SSB 6292
In CommitteeSenate
Health care financing
Establishing a joint legislative executive committee on health care financing.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill creates a special committee to study how Washington can make health care more affordable and accessible, especially as federal support declines and resources shrink. The committee will develop policy recommendations by late 2027.
- Establishes a joint legislative-executive committee on health care financing to study and recommend strategies to stabilize Washington’s health care system.
- The committee includes four legislators (two from each major caucus in House and Senate), seven state agency leaders or designees, and a tribal government representative.
- The committee must hold its first meeting by August 1, 2026, and deliver a preliminary report by January 1, 2027, and a final report by November 1, 2027.
- The committee will explore options such as health care and prescription drug purchasing strategies, provider reimbursement models, benefit design, administrative simplification, and leveraging federal funds.
- The committee may consult outside experts (e.g., health economists, providers, insurers) and may contract for economic or actuarial analysis.
- All meetings must be open to the public, with agendas and materials posted online by the Office of Financial Management.
Who is affected
- State Legislators — Members of the Washington State Legislature (House and Senate) will participate in the committee, requiring time and resources to engage in meetings and analysis.
- State Agency Leadership — State agency leaders (e.g., Health Care Authority, Department of Social and Health Services, Department of Health, Office of Financial Management, Health Benefit Exchange, Insurance Commissioner) will contribute staff time and expertise to support the committee’s work.
- Tribal Governments — Tribal governments will be represented on the committee and may be consulted on health care financing strategies affecting tribal health programs.
- General Public / Health Care Consumers — Residents of Washington State may benefit from improved health care affordability and access if the committee’s recommendations lead to policy changes.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
The committee is mandated to examine provider reimbursement models, prescription drug purchasing, and benefit design — all areas where state-level interventions (e.g., bulk purchasing, value-based payments, standardized formularies) have demonstrably reduced costs in other states, potentially lowering premiums and out-of-pocket expenses for Washingtonians.
HealthcarePeopleRef: Sec. 2(5)(a), (b), (c)By explicitly prioritizing access to and maximization of federal funds (e.g., Medicaid waivers, 90% FMAP for expansion populations, ACA subsidies), the committee could help preserve coverage for low-income residents amid federal uncertainty — directly protecting access to care for hundreds of thousands of Washingtonians.
HealthcarePeopleRef: Sec. 2(5)(e)Requiring the committee to identify at least two areas of the health system requiring direct state action creates a pathway for targeted, evidence-based reforms (e.g., price transparency, surprise billing, mental health parity enforcement) that could improve affordability and equity.
HealthcarePeopleRef: Sec. 2(5)(f)Mandating consultation with health economists, providers, and insurers — plus authorization for independent economic/actuarial analysis — increases the likelihood that recommendations will be grounded in real-world data and not ideological assumptions, improving the odds of effective, sustainable reforms.
HealthcareLean peopleRef: Sec. 2(6), (7)Public meeting requirements and online transparency ensure accountability and allow consumer advocates and community stakeholders to influence the process — increasing the chance that recommendations reflect the needs of everyday Washingtonians rather than only insurer or provider interests.
Rights & LibertiesLean peopleRef: Sec. 2(4)
Potential Concerns (5)
The bill creates a study committee but imposes no binding requirements or enforcement mechanisms on state agencies or legislators to implement recommendations, meaning outcomes are highly uncertain and may not translate into tangible improvements in health care access or affordability for Washingtonians.
Public SafetyRef: Sec. 2(5)(f)The bill’s sunset date (January 1, 2028) and lack of statutory authority to implement recommendations means any policy changes would require separate legislation, potentially delaying or diluting reforms during a period of increasing federal disengagement and rising health care costs.
Local GovernmentRef: Sec. 2(9)While leveraging federal funds is listed as a priority, the committee has no authority to negotiate or retain federal funding directly — it can only recommend strategies — limiting its ability to respond to imminent federal support declines described in the bill’s findings.
HealthcareRef: Sec. 2(5)(e)Administrative simplification is included as a goal, but without binding directives or timelines, and given the complexity of Washington’s multi-payer health system, this could result in incremental changes at best — insufficient to offset rising premiums and out-of-pocket costs for low- and middle-income families.
HealthcareRef: Sec. 2(5)(d)Benefit design and cost-sharing recommendations are left to the committee’s discretion, but without mandatory equity impact assessments or consumer representation, there is a risk that proposals could prioritize fiscal sustainability over affordability for vulnerable populations (e.g., high-deductible plans or narrow provider networks).
HealthcareRef: Sec. 2(5)(c)
Who Is Most Affected
Low- and middle-income Washingtonians — especially those on Medicaid, subsidized Marketplace plans, or struggling with high deductibles — stand to benefit if the committee recommends expansions of affordability tools (e.g., cost-sharing reductions, drug price caps, Medicaid 1115 waivers). However, they have no formal seat at the table and rely on advocacy to ensure their interests are prioritized.
Health plans and insurers may face new scrutiny on benefit design and administrative costs, but could benefit if recommendations lead to more stable risk pools or streamlined regulations. Their influence via expert consultation rights gives them outsized access to shape outcomes.
Hospitals and provider groups stand to gain or lose depending on reimbursement reforms — e.g., value-based payments could reduce volume-driven revenue, while bulk purchasing could lower drug costs. Their representation on the committee via consultation rights gives them significant informal leverage.
Tribal governments may gain insights into intergovernmental coordination on Indian Health Service funding and state-tribe health partnerships, but the bill does not guarantee increased funding or sovereignty protections for tribal health programs.
State agency staff (HCA, DSHS, DOH, OFM) will bear the operational burden of supporting the committee — including analysis, stakeholder engagement, and potential implementation planning — without new statutory authority or funding to act on recommendations.